CSF biomarkers in frontotemporal lobar degeneration: Relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 2, 2006, Pages 246-248

  Pijnenburg, Yolande A L ^a   Schoonenboom, S N M ^a,b   Barkhof, F ^b   Knol, D L ^b   Mulder, C ^b   Van Kamp, G J ^b   Van Swieten, J C ^c   Scheltens, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; BIOLOGICAL MARKER; BRAIN PROTEIN; TAU PROTEIN;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN DEGENERATION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA ISOLATION; FRONTOTEMPORAL LOBAR DEGENERATION; GENOTYPE; HUMAN; NEUROIMAGING; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; DEMENTIA; DIAGNOSTIC IMAGING; FEMALE; FRONTAL LOBE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; STATISTICS; TAU PROTEINS; TEMPORAL LOBE;

EID: 32344434409     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.066043     Document Type: Article

References (21)

1. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
2. Fabre SF, Forsell C, Viitanen M, et al. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations. Exp Neurol 2001;168:413-8.
3. Green AJ, Harvey RJ, Thompson EJ, et al. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 1999;259:133-5.
4. Riemenschneider M, Wagenpfeil S, Diehl J, et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002;58:1622-8.
5. Schoonenboom NS, Pijnenburg YA, Mulder C, et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004;62:1580-4.
6. Sjögren M, Minthon L, Davidsson P, et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontofemporal dementia, other types of dementia and normal aging. J Neural Transm 2000;107:563-79.
7. Andersen C, Froelich FS, Ostberg P, et al. Tau protein in cerebrospinal fluid from semantic dementia patients. Neurosci Lett 2000;294:155-8.
8. Maeck L, Meller J, Otto M, et al. A beta peptide(1-42), Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia. Neurosci Lett 2002;333:33-6.
9. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
11. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
12. Pijnenburg YA, Schoonenboom NS, Rosso SM, et al. CSF tau and A beta 42 are not useful in the diagnosis of frontotemporal lobar degeneration. Neurology 2004;62:1649.
13. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-34.
14. Vanderstichele H, Kerschaver E, Hesse C, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-58.
15. Scheltens P, Pasquier F, Weerts JG, et al. Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging, Eur Neurol 1997;37:95-9.
16. Jarvik GP. Genetic predictors of common disease: apolipoprotein E genotype as a paradigm. Ann Epidemiol 1997;7:357-62.
17. Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50:150-6.
18. Rosso SM, van Herpen E, Heutink P, et al. Total tau is not increased in cerebrospinal fluid of frontotemporal dementia patients with P301L and G272V tau mutations. Neurobiol Aging 2002;23:S379.
19. Strittmatter WJ, Sounders AM, Goeaert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A, 1994;91:1183-6.
20. Mann DM, McDonagh AM, Pickering-Brown SM, et al. Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype. Neurosci Lett 2001;304:161-4.
21. Vitali A, Piccini A, Borghi R, et al. Soluble amyloid beta-protein is increased in frontotemporal dementia with Tau gene mutations. J Alzheimers Dis 2004;6:45-51.